These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18584585)

  • 21. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
    Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
    Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy.
    Kelly DJ; Buck D; Cox AJ; Zhang Y; Gilbert RE
    Am J Physiol Renal Physiol; 2007 Aug; 293(2):F565-74. PubMed ID: 17522264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M
    Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Transforming growth factor-β1 regulates renal α3 and β1 integrin expressions in diabetic rats: a new insight into the renoprotective effect of irbesartan].
    Zhu Y; Shen J; Hu YY; Tang JL; Liu S
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1059-62. PubMed ID: 21690069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression.
    Chen HB; Lu JX; Li Q; Bao YQ; Tang JL; Lu HJ; Xiang KS; Jia WP
    Acta Pharmacol Sin; 2009 Feb; 30(2):242-50. PubMed ID: 19169272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
    Qin J; Zhang Z; Liu J; Sun L; Hu L; Cooper ME; Cao Z
    Kidney Int; 2003 Aug; 64(2):565-71. PubMed ID: 12846751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli.
    Nakamura T; Ebihara I; Fukui M; Tomino Y; Koide H
    Diabetes; 1995 Aug; 44(8):895-9. PubMed ID: 7621993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells.
    Matsui T; Nishino Y; Maeda S; Takeuchi M; Yamagishi S
    Microvasc Res; 2011 May; 81(3):269-73. PubMed ID: 21236267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat.
    Kelly DJ; Skinner SL; Gilbert RE; Cox AJ; Cooper ME; Wilkinson-Berka JL
    Kidney Int; 2000 May; 57(5):1882-94. PubMed ID: 10792607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
    Motawi TK; El-Maraghy SA; Senousy MA
    J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
    Hartner A; Cordasic N; Klanke B; Menendez-Castro C; Veelken R; Schmieder RE; Hilgers KF
    Biochim Biophys Acta; 2014 Apr; 1842(4):558-65. PubMed ID: 24418215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli.
    Banes AK; Shaw S; Jenkins J; Redd H; Amiri F; Pollock DM; Marrero MB
    Am J Physiol Renal Physiol; 2004 Apr; 286(4):F653-9. PubMed ID: 14678947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glomerular repair retardation via blocking of angiotensin II type 1a receptor pathway in a mouse glomerulonephritis model.
    Hayashi W; Obata Y; Nishino T; Abe S; Io K; Furusu A; Abe K; Miyazaki M; Sugaya T; Koji T; Kohno S
    Nephron Exp Nephrol; 2012; 122(1-2):13-22. PubMed ID: 23446008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of selective cyclooxygenase -2 inhibitor on the renal lesion of streptozotocin-induced diabetic rats and its possible mechanism].
    Zuo Y; Gu Y; Ma J; Lin S
    Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):239-43. PubMed ID: 11953170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes.
    Iglesias-de la Cruz MC; Ziyadeh FN; Isono M; Kouahou M; Han DC; Kalluri R; Mundel P; Chen S
    Kidney Int; 2002 Sep; 62(3):901-13. PubMed ID: 12164872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
    Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
    Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli.
    Xu ZG; Yoo TH; Ryu DR; Cheon Park H; Ha SK; Han DS; Adler SG; Natarajan R; Kang SW
    Kidney Int; 2005 Mar; 67(3):944-52. PubMed ID: 15698433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
    Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
    Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
    Kelly DJ; Cox AJ; Tolcos M; Cooper ME; Wilkinson-Berka JL; Gilbert RE
    Kidney Int; 2002 Jan; 61(1):31-9. PubMed ID: 11786082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.